In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Colon and Rectal Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Neoadjuvant Therapy for Rectal Cancer
    (Posted: 05/09/2006) - With this trial, researchers hope to improve neoadjuvant therapy for rectal cancer with the use of oral capecitabine and addition of oxaliplatin and, through the collection of tissue samples, learn how to identify those patients who will benefit from neoadjuvant therapy.
  • Adjuvant Therapy for Stage II Colon Cancer
    (Posted: 03/14/2006) - In this trial, researchers are using molecular tests to help identify patients who are at high risk for recurrence after colon cancer surgery. High-risk patients will receive adjuvant chemotherapy (drug therapy given after surgery to help suppress cancer recurrence). Some of these patients will also receive bevacizumab. Low-risk patients will be observed but will not receive adjuvant therapy.
  • Combination Therapy for Liver Metastases Resulting from Colorectal Cancer
    (Posted: 09/27/2005) - In this study, researchers are combining local treatment through isolated hepatic perfusion (IHP) and standard systemic chemotherapy to determine whether this combined approach may prolong the lives of patients with liver metastases secondary to colorectal cancer.
  • Adjuvant Therapy for Patients with Colon Cancer
    (Posted: 08/02/2005) - With this study, researchers hope that patients undergoing adjuvant treatment for colon cancer that has not metastasized will also benefit from the addition of bevacizumab to chemotherapy.
  • Targeted Combination Therapy for Advanced Solid Tumors
    (Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.
< Previous  1 2 3 4